H2020-JTI-IMI2-2016-10-two-stage
H2020-JTI-IMI2-2016-10-two-stage
- Programme
- H2020
- Funded projects (dataset)
- 8
- EU contribution (sum)
- €173,874,258
- Portal deadline
- —
Leading topic in historical projects: IMI2-2016-10-01
Start here
Suggested partners for this call
Who coordinated consortia under this call, plus a complementary slice (topic leaders, research partners, or frequent non-coordinators). For industry lists, CSV export, and consortium size — open Proposal partner finder.
Top coordinators
Organisations that coordinated the most funded projects under this call.
- CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH1 coordinated
- FONDAZIONE PENTA ETS1 coordinated
- EUROPEAN PATIENTS FORUM1 coordinated
- KING'S COLLEGE LONDON1 coordinated
- KTH1 coordinated
- UHEI1 coordinated
- EAU1 coordinated
- RADBOUDUMC1 coordinated
Organisations strong on this topic
Broader signal: frequent participants across funded projects tagged with the same topic codes as this call (not limited to coordinators).
- BAYER AKTIENGESELLSCHAFT2 topic projects
- ELI LILLY AND COMPANY LTD2 topic projects
- REGIONH2 topic projects
- UEDIN2 topic projects
- AAU1 topic projects
- AU1 topic projects
- ADC1 topic projects
- Actual Analytics1 topic projects
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1 topic projects
- ASSOC EISBM1 topic projects
- YAMANOUCHI EUROPE BROCADES PHARMA1 topic projects
Frequent collaborators
Pairs that often appear together in the same funded project under this call.
- BAYER AKTIENGESELLSCHAFT · PFIZER4 shared
DE ↔ UK
- 4 shared
- BAYER AKTIENGESELLSCHAFT · NOVARTIS4 shared
DE ↔ CH
- SARD · BAYER AKTIENGESELLSCHAFT4 shared
FR ↔ DE
- RADBOUDUMC · STICHTING RADBOUD UNIVERSITEIT3 shared
NL ↔ NL
- JANSSEN PHARMACEUTICA NV · FSJD-CERCA3 shared
BE ↔ ES
- 3 shared
- ROCHE · FSJD-CERCA3 shared
CH ↔ ES
- JANSSEN PHARMACEUTICA NV · SARD3 shared
BE ↔ FR
- 3 shared
- 3 shared
- JANSSEN PHARMACEUTICA NV · NOVARTIS3 shared
BE ↔ CH
- 3 shared
- RADBOUDUMC · KING'S COLLEGE LONDON3 shared
NL ↔ UK
- JANSSEN PHARMACEUTICA NV · RADBOUDUMC3 shared
BE ↔ NL
- JANSSEN PHARMACEUTICA NV · UCB3 shared
BE ↔ BE
- JANSSEN PHARMACEUTICA NV · ROCHE3 shared
BE ↔ CH
- 3 shared
Proposal partner finder
One page with suggested coordinators, strong and industry partners, topic leaders, typical consortium size, similar projects — plus CSV or print / PDF export for your shortlist.
Typical consortium pattern
Derived from historical funded projects linked to this CORDIS call in Grantibase.
- Avg. orgs / project
- 37.25
- Median orgs / project
- 35
- Min / max orgs
- 14 – 64
Country presence
Participant rows (an org can appear in multiple countries if data varies).
- United Kingdom56
- Germany42
- Netherlands31
- Belgium29
- Italy24
- France22
- Spain19
- Switzerland15
- Denmark11
- Sweden10
- United States9
- Finland4
- Austria4
- Ireland4
- Portugal4
- Israel3
- Czechia2
- Poland1
Organization types
- university73 orgs · 94 rows
- company43 orgs · 77 rows
- research_institute42 orgs · 49 rows
- other35 orgs · 36 rows
- sme29 orgs · 29 rows
- public_body11 orgs · 13 rows
Topics in funded projects
- IMI2-2016-10-01IMI2-2016-10-01· 1 projects
- IMI2-2016-10-02IMI2-2016-10-02· 1 projects
- IMI2-2016-10-03IMI2-2016-10-03· 1 projects
- IMI2-2016-10-04IMI2-2016-10-04· 1 projects
- IMI2-2016-10-05IMI2-2016-10-05· 1 projects
- IMI2-2016-10-06IMI2-2016-10-06· 1 projects
- IMI2-2016-10-07IMI2-2016-10-07· 1 projects
- IMI2-2016-10-08IMI2-2016-10-08· 1 projects
Related funded projects
Largest EU contributions in this call — useful to see who already won funding on similar lines.
Open full project list in advanced search
| Project | Programme | EU contribution |
|---|---|---|
| c4c conect4children (COllaborative Network for European Clinical Trials For Children) | H2020 | €67,000,000 |
| AIMS-2-TRIALS Autism Innovative Medicine Studies – 2 – Trials | H2020 | €54,999,999 |
| Hypo-RESOLVE Hypoglycaemia - REdefining SOLutions for better liVEs | H2020 | €13,450,057 |
| ReSOLUTE Research empowerment on solute carriers (ReSOLUTE) | H2020 | €12,000,000 |
| IMI-PainCare Improving the care of patients suffering from acute or chronic pain | H2020 | €11,225,271 |
| PIONEER Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope | H2020 | €6,000,000 |
| iConsensus Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production | H2020 | €4,700,000 |
| PARADIGM Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. | H2020 | €4,498,931 |